Bitdeer Announces February 2025 Production and Operations Update
- SEAL03 sample wafers achieved a power efficiency of 9.7 J/TH at the chip level during chip verification and prototype testing while running at low voltage, ultra power-saving mode
- Anticipate SEALMINER A3 mass production to commence in the latter half of 2025
SINGAPORE, March 12, 2025 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) ('Bitdeer' or the 'Company'), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited mining and operations updates for February 2025.
Operational Update
Self-mined Bitcoin: 110 bitcoins, down from January 2025 due to less days in February.
Mining Rig Manufacturing and R&D:
SEALMINER A1:
Mass production of approximately 3.7 EH/s of mining rigs is nearly finalized.
0.7 EH/s are energized, 0.4 EH/s have been delivered for installation, 0.2 EH/s are in-transit to datacenters, 2.3 EH/s have been produced and ready for shipment and 0.1 EH/s remain in production. We expect to ship all remaining mining machines to mining facilities in March 2025.
SEALMINER A2:
Production of approximately 35 EH/s are expected to be completed in October 2025, of which 0.6 EH/s have been produced and are ready for shipment. We expect approximately another 1 EH/s to be manufactured in March 2025.
Approximately 7 EH/s out of the 35 EH/s of SEALMINER A2s allocated for external sales are expected to begin shipment in March 2025.
Recently, certain customers have requested to delay their final payment for SEALMINER A2s due to lower Bitcoin price. Furthermore, they have also requested alternative purchase options for future generations of SEALMINER machines. As such, Bitdeer plans to redirect SEALMINER A2s previously allocated for external sale to self-mining to avoid idle inventory. However, the Company is confident that all 7 EH/s will be sold in the near future.
While allowing customers to delay final payment, Bitdeer will retain customers' down payment on SEALMINER A2s.
SEALMINER A3:
SEAL03 sample wafers achieved an energy efficiency of 9.7 J/TH at the chip level during chip verification and prototype testing while running at low voltage, ultra power-saving mode.
SEALMINER A4:
SEAL04 R&D remains on track to achieve an expected chip efficiency of approximately 5 J/TH with anticipated initial tape-out in Q3 2025.
HPC/AI:
Discussions are ongoing with multiple development partners and potential end users for select large scale sites in U.S. for HPC/AI.
Hosting:
Client-hosted machines decreased by 17,000 units or 1.7 EH/s in February, due to customers kept disposing their less efficient mining rigs.
Infrastructure:
Tydal, Norway, 40 MW phase 1 expansion energization application has entered into the fast track for final regulatory approval.
Rockdale, Texas, USA, 100 MW hydro-cooling conversion is on track to commence phased energization in March 2025, of which approximately half of the capacity will be used for operating SEALMINER A1 Hydro-cooled machines. As of the date of this report, more than 500 units of SEALMINER A1 Hydro-cooled machines have already been energized, running stably with very low defective rate and the Company expects more SEALMINER A1 Hydro-cooled and SEALMINER A2 series mining rigs will be delivered to Rockdale, Texas in March 2025.
Clarington Phase 2, Ohio, USA, 304 MW is still pending approval and in negotiation with the landlord.
Jigmeling, Bhutan, 500 MW construction is on track with the primary substation expected to be completed by the end of March 2025.
Share Repurchase:
Completed the repurchased approximately US$9 million of the Company's Class A ordinary shares at the end of February 2025 while the share price dropped significantly.
The Company's board of directors approved a new share repurchase program to repurchase up to additional US$20 million worth of its Class A ordinary shares effective from February 28, 2025 through February 28, 2026.
Management Commentary
We expect nearly all SEALMINER A1s to be energized during March and April 2025. Further, we remain focused on executing our chip roadmap on SEALMINER A2 and SEALMINER A3. We will leverage our massive 2.6 GW power portfolio for HPC/AI. We have advanced discussions with multiple development partners and potential end users for selecting large scale sites in U.S. and hope to provide an update to investors in the coming months.
Production and Operations Summary
Metrics Feb 2025 Jan 2025 Dec 2024
Total hash rate under management1 (EH/s) 20.9 22.4 21.6
- Proprietary hash rate 9.4 9.2 8.9
• Self-mining 9.0 8.7 8.5
• Cloud Hash Rate - - -
• Delivered but not hashing 0.4 0.5 0.4
- Hosting 11.5 13.2 12.7
Mining machines under management 163,000 179,000 175,000
- Self-owned2 88,000 87,000 85,000
- Hosted 75,000 92,000 90,000
Bitcoins mined (self-mining only) 110 126 145
Bitcoin held3 1,039 724 594
1 Total hash rate under management as of February 28, 2025 across the Company's three primary business lines: Self-mining, Cloud Hash Rate, and Hosting.
Self-mining refers to cryptocurrency mining for the Company's own account, which allows it to directly capture the high appreciation potential of cryptocurrency.
Cloud Hash Rate offers hash rate subscription plans and shares mining income with customers under certain arrangements. The Cloud Hash Rate stated above reflects the contracted hash rate with customers at month-end.
Hosting encompasses a one-stop mining machine hosting solution including deployment, maintenance, and management services for efficient cryptocurrency mining.
2 Self-owned mining machines are for the Company's self-mining business and Cloud Hash Rate business.
3 Bitcoins held do not include the Bitcoins from deposits of the customers.
Additional Details Regarding CEO's Rule 10b5-1 Plan
As previously announced on February 25, 2025, Chairman of the Board and Chief Executive Officer, Jihan Wu, has adopted a plan to sell up to 4 million ordinary shares of the Company on multiple pre-determined dates starting in March 2025 and ending no later than the earlier of June 15, 2025 or the date that the aggregate number of ordinary shares sold under the Plan reaches 4 million. The plan was designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the 'plan'). The Company was informed of the terms of the plan as follows:
1 million Class A ordinary shares may be sold under the plan if the price per share is $16.5 or higher,
2 million shares may be sold under the plan if the price per share is $26.7 or higher,
3 million shares may be sold under the plan if the price per share is $43.2 or higher, and
4 million shares may be sold under the plan if the price per share is $69.9 or higher.
The number of shares to be sold under the plan on each trading day shall not exceed 8% of the reported daily trading volume of the shares on such day.
Infrastructure Construction Update
Rockdale, Texas – 100 MW Hydro-cooling conversion energization commenced:
Cooling system will be delivered and installed in phases in Q1 2025.
Energization began in early March 2025.
Planning for energization in accordance with the phase of delivery of mining rigs.
Tydal, Norway – 175 MW site expansion anticipated to be fully energized by mid-2025:
Installation of the transformers has been completed, with the delivery and installation of electrical equipment currently in progress. Additionally, the procurement and delivery of containers and hydro-cooling systems are underway, and drainage systems construction is ongoing.
Tydal, Norway Phase 1 40 MW expansion pending regulatory approval. Energization of the full 175 MW site is expected to occur no later than mid-2025, subject to regulatory approval.
Massillon, Ohio – 221 MW site construction has begun ahead of schedule:
Substation construction is underway and is expected to be completed in Q3 2025.
Building design is completed and construction has begun earlier than expected, estimated to be completed in phases between Q3 and Q4 2025.
Estimated energization is expected to be completed in phases over Q3 and Q4 2025.
Clarington Phase 2, Ohio – 304 MW is still pending approval and in negotiation with the landlord.
Jigmeling, Bhutan – 500 MW site is progressing well, with the following key milestones achieved:
Construction of transformer and container foundations in progress and will be completed in phases, with the last phase expected by the end of March 2025.
132kv/140MW and 220kv/360MW substation designs are completed, and construction will be completed in phases over Q1 and Q2 2025.
Orders for the procurement of transformers and electrical equipment have been placed, with delivery and installation work to be completed in phases over Q1 and Q2 2025.
Procurement and delivery of containers and hydro-cooling systems are in progress, will be completed in phases over Q1 and Q2 2025.
Fox Creek, Alberta – 101 MW site acquired in Alberta sits on 19 acres is fully licensed and permitted:
Acquisition includes all permits and licenses to construct an on-site natural gas power plant, as well as approval for a 99 MW grid interconnection with Alberta Electric System Operator ('AESO').
Bitdeer will develop and construct the power plant in partnership with a leading Engineering, Procurement and Construction ('EPC') company and is expected to be energized by Q4 2026.
Site / Location Capacity (MW) Status Timing4
Electrical capacity
- Rockdale, Texas 563 Online Completed
- Knoxville, Tennessee 86 Online Completed
- Wenatchee, Washington 13 Online Completed
- Molde, Norway 84 Online Completed
- Tydal, Norway 50 Online Completed
- Gedu, Bhutan 100 Online Completed
Total electrical capacity 8955
Pipeline capacity
- Tydal, Norway Phase 1 40 In progress Pending Regulatory Approval
- Tydal, Norway Phase 2 135 In progress Mid 2025
- Massillon, Ohio 221 In progress Q4 2025
- Clarington, Ohio Phase 1 266 In progress Q3 2025
- Clarington, Ohio Phase 2 304 Pending approval Estimate 2026
- Jigmeling, Bhutan 500 In progress Mid-to-late 2025
- Rockdale, Texas 179 In planning Estimate 2026
- Alberta, Canada 99 In planning Q4 2026
Total pipeline capacity 1,744
Total global electrical capacity 2,639
4 Indicative timing. All timing references are to calendar quarters and years.
5 Figures may not add up due to rounding.
Upcoming Conferences and Events
March 11 – 12, 2025: Cantor Global Technology Conference in New York City
March 16 – 18, 2025: 37th Annual ROTH Growth Conference in Dana Point, California
March 18 – 20, 2025: Jefferies 6th Asia Forum in Hong Kong
April 8, 2025: JonesResearch Healthcare and Technology Innovation Conference in Las Vegas, Nevada
May 21 – 22, 2025: B. Riley 25th Annual Investor Conference in Marina del Rey
May 28, 2025: Orange Group 2nd Annual Sell-side and Buy-side Conference during Bitcoin 2025 in Las Vegas, Nevada
About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. Bitdeer is committed to providing comprehensive computing solutions for its customers. The Company handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The Company also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed datacenters in the United States, Norway, and Bhutan. To learn more, visit https://ir.bitdeer.com/ or follow Bitdeer on X @ BitdeerOfficial and LinkedIn @ Bitdeer Group.
Investors and others should note that Bitdeer may announce material information using its website and/or on its accounts on social media platforms, including X, formerly known as Twitter, Facebook, and LinkedIn. Therefore, Bitdeer encourages investors and others to review the information it posts on the social media and other communication channels listed on its website.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'look forward to,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled 'Risk Factors' in Bitdeer's annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer's subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.
For investor and media inquiries, please contact:
Investor Relations
Orange Group
Public Relations
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Yahoo
28 minutes ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool
Associated Press
28 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Red Cat Holdings
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Red Cat To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Red Cat Holdings, Inc. ('Red Cat' or the 'Company') (NASDAQ: RCAT) and reminds investors of the July 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. In March 2022, Red Cat announced that Teal had been selected by the U.S. Department of Defense's Defense Innovation Unit and the U.S. Army to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program'). The SRR Program is a U.S. Army initiative to provide a small, rucksack-portable sUAS to U.S. Army platoons. At all relevant times, Defendants suggested or otherwise asserted that the SRR Program's Tranche 2 contract (the 'SRR Contract') was worth potentially hundreds of millions to over a billion dollars in contract revenues. In March 2023, Company management confirmed that "[t]he Salt Lake City factory is complete and ready to go' and "[w]e now have the capacity to produce thousands of drones per month.' The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (ii) the overall value of the SRR Contract was overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On July 27, 2023, Red Cat hosted a conference call with investors and analysts to discuss its financial and operating results for its fiscal year 2023. During the call, Defendants revealed that the Salt Lake City Facility could only currently produce 100 drones per month, and that the facility was still being built, refined, and expanded. Red Cat filed an annual report on Form 10-K with the U.S. Securities and Exchange Commission the same day, which likewise reported that construction of the facility was only 'substantially completed' and potentially could reach a production capacity of one thousand drones per month over the next 2 to 3 years, but only with additional capital investments and manufacturing efficiencies realized. Following these disclosures, Red Cat's stock price fell $0.10 per share, or 8.93%, to close at $1.02 per share on July 28, 2023. On September 23, 2024, Red Cat issued a press release announcing its financial and operating results for the first quarter of its fiscal year 2025. Among other results, the Company reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing consensus estimates by $1.07 million. On a subsequent conference call that Red Cat hosted with investors and analysts the same day to discuss these results, Company management disclosed that Red Cat had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because, inter alia, Red Cat 'couldn't produce and sell Teal 2 units[] while retooling [its] factory.' On this news, Red Cat's stock price fell $0.80 per share, or 25.32%, over the following two trading sessions, to close at $2.36 per share on September 25, 2024. On November 19, 2024, Red Cat issued a press release announcing that it had won the SRR Contract. On a subsequent conference call that Red Cat hosted with investors and analysts the same day to discuss the contract win, Defendants continued to assert that the SRR Contract was worth potentially hundreds of millions of dollars, while expressing their confidence that Red Cat could realize up to $50 million to $79.5 million in revenue from the SRR Contract during it fiscal year 2025 alone. Then, on January 16, 2025, Kerrisdale Capital ('Kerrisdale') published a report (the 'Kerrisdale Report') alleging, inter alia, that Defendants had overstated the value of the SRR Contract, which Kerrisdale found was only worth approximately $20 million to $25 million based on U.S. Army budget documents. The Kerrisdale Report also alleged that Defendants had been misleading investors about the Salt Lake City Facility's production capacity for years, while also raising concerns about the timing of executive departures and insider transactions that took place shortly after Red Cat announced it had won the SRR Contract. On this news, Red Cat's stock price fell $2.35 per share, or 21.54%, over the following two trading sessions, to close at $8.56 per share on January 17, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Red Cat's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Red Cat class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
